You are here

Cancer Discov DOI:10.1158/2159-8290.CD-13-0310

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Publication TypeJournal Article
Year of Publication2013
AuthorsAkbay, EA, Koyama, S, Carretero, J, Altabef, A, Tchaicha, JH, Christensen, CL, Mikse, OR, Cherniack, AD, Beauchamp, EM, Pugh, TJ, Wilkerson, MD, Fecci, PE, Butaney, M, Reibel, JB, Soucheray, M, Cohoon, TJ, Jänne, PA, Meyerson, M, D Hayes, N, Shapiro, GI, Shimamura, T, Sholl, LM, Rodig, SJ, Freeman, GJ, Hammerman, PS, Dranoff, G, Wong, K-K
JournalCancer Discov
Volume3
Issue12
Pages1355-63
Date Published2013 Dec
ISSN2159-8290
KeywordsAnimals, Antigens, CD274, Carcinoma, Non-Small-Cell Lung, Cell Line, Cytokines, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms, Lymphocyte Activation, Mice, Mice, Inbred C57BL, Mice, Transgenic, Oncogenes, Programmed Cell Death 1 Receptor, Receptor, Epidermal Growth Factor, Signal Transduction, T-Lymphocytes, Tumor Escape, Tumor Microenvironment
Abstract

UNLABELLED: The success in lung cancer therapy with programmed death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between EGF receptor (EGFR) pathway activation and a signature of immunosuppression manifested by upregulation of PD-1, PD-L1, CTL antigen-4 (CTLA-4), and multiple tumor-promoting inflammatory cytokines. We observed decreased CTLs and increased markers of T-cell exhaustion in mouse models of EGFR-driven lung cancer. PD-1 antibody blockade improved the survival of mice with EGFR-driven adenocarcinomas by enhancing effector T-cell function and lowering the levels of tumor-promoting cytokines. Expression of mutant EGFR in bronchial epithelial cells induced PD-L1, and PD-L1 expression was reduced by EGFR inhibitors in non-small cell lung cancer cell lines with activated EGFR. These data suggest that oncogenic EGFR signaling remodels the tumor microenvironment to trigger immune escape and mechanistically link treatment response to PD-1 inhibition.

SIGNIFICANCE: We show that autochthonous EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase levels of proinflammatory cytokines. These findings indicate that EGFR functions as an oncogene through non-cell-autonomous mechanisms and raise the possibility that other oncogenes may drive immune escape.

URLhttp://cancerdiscovery.aacrjournals.org/cgi/pmidlookup?view=long&pmid=24078774
DOI10.1158/2159-8290.CD-13-0310
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/24078774?dopt=Abstract

Alternate JournalCancer Discov
PubMed ID24078774
PubMed Central IDPMC3864135
Grant ListP50CA090578 / CA / NCI NIH HHS / United States
CA166480 / CA / NCI NIH HHS / United States
R01 CA122794 / CA / NCI NIH HHS / United States
K08 CA163677 / CA / NCI NIH HHS / United States
1K08CA163677 / CA / NCI NIH HHS / United States
P01 CA078378 / CA / NCI NIH HHS / United States
CA163896 / CA / NCI NIH HHS / United States
P01 CA154303 / CA / NCI NIH HHS / United States
P01 CA155258 / CA / NCI NIH HHS / United States
R01 CA163896 / CA / NCI NIH HHS / United States
R01 CA166480 / CA / NCI NIH HHS / United States
CA122794 / CA / NCI NIH HHS / United States
R01 CA140594 / CA / NCI NIH HHS / United States
CA140594 / CA / NCI NIH HHS / United States
P50 CA090578 / CA / NCI NIH HHS / United States
R01 CA116020 / CA / NCI NIH HHS / United States
R01 CA143083 / CA / NCI NIH HHS / United States
CA154303 / CA / NCI NIH HHS / United States
P50 CA100707 / CA / NCI NIH HHS / United States
U54CA163125 / CA / NCI NIH HHS / United States
R01CA143083 / CA / NCI NIH HHS / United States